LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody ® First-in-human study enrolling adult patients with ...

Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Hold ...

PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment of ...

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced dosing ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...

Medically reviewed by Doru Paul, MD Leukemia is a cancer of the blood-forming tissues that often develops in the bone marrow.

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Texas Tech Physicians nurse practitioner Sara Tello recommended a comprehensive and compassionate approach for people trying to quit smoking, v ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Aptose Biosciences (APTO) announced dosing the first set of patients in the TUSCANY Phase 1/2 study with tuspetinib in combination with ...

TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AMLSAN DIEGO and ...